We carried out a comparative study in 50 hospitalized COLD patients in order to evaluate the clinical effectiveness of sustained-release ambroxol against ambroxol. According to a randomized trial 25 patients (mean age 59,2±3,5 years) received sustained-release ambroxol at the dose of 150 mg per day (2 tablets in a single administration) for 8 days and then 75 mg until the end of a 15 day long treatment. The other 25 patients (mean age 63±3,1) received ambroxol at the dose of 90 mg per day (a 30 mg table three times per day) for 8 days and then 60 mg until the 15th day of treatment. At the beginning of the study, on the 1st, 2nd, 3rd, 4th, and then every two days we evaluated the volume and characteristics of sputum, symptoms (cough, wheeziness and difficulty in coughing up) and objective clinical signs. We observed in both groups a progressive reduction of baseline sputum volume (-26 and 30% after 4 days, -41 and 42% after 8 days, -65 and 70% at the end of treatment for sustained release ambroxol and ambroxol, respectively), a reduction in sputum viscosity (3,8→2.4 and 3.4→2, respectively) and an improvement in the clinical state of the patients. The drug appeared to be well tolerated, since we observed no adverse reaction of any importance, either seen by the physicians or shown by laboratory examinations. So we can conclude that both sustained-release ambroxol and ambroxol have a prolonged and favourable effect either in reducing sputum viscosity or in improving the well-being of the patient.
|Translated title of the contribution||Sustained release formulation of ambroxol in medium-term treatment of chronic obstructive bronchopneumopathy|
|Number of pages||6|
|Publication status||Published - 1985|
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine